An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune ...

The growing demand for immune checkpoint inhibitors is mainly driven by the rising incidence of lung cancer, the increasing prevalence of melanoma, and the expanding number of research studies related ...

Use of immune checkpoint inhibitor (ICI) therapy for cancer was associated with a significant reduction in actinic keratoses ...

Bristol-Myers Squibb has won FDA approval for the first ... BMS' notoriously hard to tolerate CTLA4 checkpoint inhibitor – which has been approved as a monotherapy for melanoma since 2011 ...

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatment for skin cancer.

Predicting how cancer patients will respond to treatment remains a critical challenge. Immune checkpoint inhibitors (ICIs), a ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25 ... and impact on immune function await longer-term trials, to date, this agent appears ...

This approach also helped make treatment with immune checkpoint inhibitors more effective. Several nanoparticle-based delivery systems are approved by the FDA for cancer treatments. These systems ...

IFx-2.0 is scheduled to begin its Phase III study in 1H:25 under a Special Protocol Assessment (SPA) agreement with the FDA ... primary resistance to checkpoint inhibitor therapy and may provide ...

IPH5201, which is being developed by Innate Pharma and AstraZeneca, is currently under investigation in conjunction with immune checkpoint inhibitors (ICIs) to enhance the immune response in ...